DIVISLAB
DIVISLAB · NSE
₹11,180.5
+0.02% (+₹2.5)
Prev. close
₹11,178
Volume
4,04,825
Delivery %
63.0%
As of
20 Nov 2026
Price history
Ajit Mishra · Religare Broking · 25 Mar 2025, 09:17 IST
“Bullish on Divi’s Laboratories, recommending a buy with a target of ₹6300 and a stop loss at ₹5720 for a short-term trading horizon.”
Entry ≈ ₹5,869.85 (first trade after call)Target ₹6,300 (+7.3%)Stop ₹5,720 (-2.6%)R:R ~2.9:1Stopped out · 01 Apr 2025
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
| Call | Analyst | Instrument | Verdict | Actions | |||
|---|---|---|---|---|---|---|---|
| “Bullish on Divi's Laboratories, expecting the stock to move towards ₹10,000. He notes consistent buying interest during …” | Rahul SharmaJM Financial Services | Divi's Laboratories | HIT | ||||
| “Bullish on Divis Laboratories, recommending a buy with a target price of ₹10,000 and a stop loss of ₹9,400. The stock is…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Divis Laboratories | MISS | ||||
| “Bullish on Divis Laboratories with a target price of ₹9,800 and a stop loss of ₹9,050. The stock is in an overall uptren…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Divis Laboratories | MISS | ||||
| “Recommends accumulating Divi's Laboratories with a target price of ₹6,795. The call implies a bullish outlook on the sto…” | Deven ChokseyIndependent | Divi's Laboratories | HIT | ||||
| “Recommends accumulating Divi's Laboratories with a target price of ₹7,050. The call implies a bullish outlook on the sto…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Divi's Laboratories | HIT | ||||
| “Bullish on Divi’s Laboratories Ltd, recommending a buy at ₹6,474.50 with a target of ₹6,682 and a stop loss at ₹6,373. T…” | Ankush BajajIndependent | Divi’s Laboratories Ltd | HIT | ||||
| “Bullish on Divi's Laboratories, which has reversed from oversold levels near ₹5,700 and is set for a move towards ₹6,600…” | Rahul SharmaJM Financial Services | Divi's Laboratories | HIT | ||||
| “Upgraded Divi’s Laboratories to 'Buy', setting a target price of Rs 7,150, indicating a 19% upside from the closing pric…” | Jefferies AnalysisJefferies | Divi's Laboratories Ltd | HIT | ||||
| “Recommends accumulating Divi's Laboratories with a target price of ₹6,550. The call implies a bullish outlook on the sto…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Divi's Laboratories | HIT | ||||
| “Bullish on Divi's Laboratories, recommending a buy at ₹6,983 with a target price of ₹7,125–₹7,140 and a stop loss at ₹6,…” | Ankush BajajIndependent | Divi's Laboratories | NOT TRIGGERED | ||||
| “Bullish on Divi's Laboratories for July 10, targeting ₹7,125–₹7,140, with a stop loss at ₹6,910. The stock shows strong …” | Ankush BajajIndependent | Divi's Laboratories | MISS | ||||
| “Recommends buying Divis Laboratories Futures in the ₹6,820-₹6,830 range with a stop loss at ₹6,650 and targets of ₹7,050…” | Jay ThakkarICICI Securities | Divis Laboratories | MISS | ||||
| “Recommends buying Divi’s Laboratories Ltd with a target of Rs 7,180 and a stop loss at Rs 6,600 for a short-term trading…” | Ajit MishraReligare Broking | Divi's Laboratories Ltd | MISS | ||||
| “Recommends accumulating Divi's Laboratories with a target price of ₹7,518. The call implies a bullish outlook on the sto…” | Devan ChokseyIndependent | Divi's Laboratories | MISS | ||||
| “Bullish on Divi's Labs futures in the near-term, recommending a buy between 6530-6560 with a stop loss at 6350 and targe…” | Jay ThakkarICICI Securities | Divi's Laboratories | MISS | ||||
| “Recommends buying Divi's Laboratories Ltd with a target of Rs 7,150 and a stop loss at Rs 6,300 for short-term traders.” | Ajit MishraReligare Broking | Divi's Laboratories | MISS | ||||
| “Bullish on Divi's Laboratories for the near term, targeting ₹7,150 and ₹7,300, with a stop loss at ₹6,200. The stock has…” | Vishnu Kant UpadhyayMaster Capital Services | Divi's Laboratories | MISS | ||||
| “Bullish on Divis Laboratories, which has broken out of a six-month consolidation, signaling an end to the sideways movem…” | Sagar DoshiNuvama Professional Clients Group | Divis Laboratories Ltd | HIT | ||||
| “Bullish on Divi’s Laboratories, recommending a buy with a target of ₹6300 and a stop loss at ₹5720 for a short-term trad…” | Ajit MishraReligare Broking | Divi's Laboratories | MISS | ||||
“Bullish on Divi’s Laboratories, recommending a buy with a target of ₹6300 and a stop loss at ₹5720 for a short-term trading horizon.” How this call is judged A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. No entry price is stated, so the call starts at the first close after it was published. Target ₹6,300, stop ₹5,720, as stated. No time frame is stated, so it is tracked until a close reaches ₹6,300 or ₹5,720: there is no fixed window. The stop ₹5,720 was reached on a close before the target ₹6,300. Miss. The grader's working: R4 TARGET_CALL: entered ₹5839.2 on 2025-03-26 (next trading session's close); stop ₹5720 breached at close ₹5549.7 on 2025-04-01. No time frame is stated and the call gives both a target and a stop, so it is tracked until a close reaches one of them (rule H6): the target first is a hit, the stop first a miss, and until then it stays open. (01 Apr 2025) | |||||||
| “Recommends buying Divis Laboratories (DIVISLAB) at ₹5615, with a stop loss at ₹5550 for a target price of ₹5750. The sto…” | Ganesh DongreAnand Rathi | Divis Laboratories Ltd | HIT | ||||
| “Recommends buying Divis Laboratories at ₹5675, with a stop loss at ₹5550 for a target price of ₹5900. The stock is in an…” | Ganesh DongreAnand Rathi | Divis Laboratories Ltd | HIT | ||||
| “Bullish on Divi’s Laboratories with a price target of ₹6,850, reflecting a 23% upside. Expects over 25% earnings growth …” | Private Bank Trader AnalysisPrivate Bank Trader | Divi's Laboratories Ltd | HIT | ||||
| “Bullish on Divi's Laboratories with an 'outperform' rating and a target price of ₹7,400, implying a 26.8% upside. Expect…” | Macquarie AnalysisMacquarie Capital Securities | Divi's Laboratories | MISS | ||||
| “Bullish on Divi’s Laboratories with a target of ₹6,060 and a stop loss at ₹5,880 for a short-term trading horizon.” | Kunal BothraIndependent | Divi's Laboratories | MISS | ||||
| “Maintains a 'SELL' rating on Divi's Laboratories with an unchanged target price of ₹4,500, based on 45x FY26E earnings. …” | ICICI Securities AnalysisICICI Securities | Divi's Laboratories | MISS | ||||
| “Recommends accumulating Divi's Laboratories with a target price of ₹6,250. The call implies a bullish outlook on the sto…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Divi's Laboratories | PENDING | ||||
| “Maintained a 'Buy' rating on Divi's Labs with a target price of ₹6,830. The company delivered strong Q3FY25 performance,…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Divi's Laboratories | HIT | ||||
| “Nuvama maintains a 'BUY' rating on Divi's Laboratories with an unchanged target price of ₹6,830. The company outperforme…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Divi's Laboratories | HIT | ||||
| “Divis Laboratories is showing signs of strength at ₹5,810 after consolidation, bouncing from support near ₹5,355-5,400. …” | Ameya RanadiveStoxBox | Divi's Laboratories Ltd | MISS | ||||
| “Recommends selling Divi’s Laboratories with a target of ₹5260 and a stop loss at ₹5730 for a short-term trading horizon.” | Ajit MishraReligare Broking | Divi's Laboratories | MISS | ||||
| “Bullish on Divis Lab, recommending a buy at ₹5,762 with a target of ₹5,820-5,850 and a stop loss at ₹5,700. The stock sh…” | Ankush BajajIndependent | Divi's Laboratories Ltd | HIT | ||||
| “Bullish on Divi's Lab, recommending a buy at ₹5,762 with a target price range of ₹5,820-5,850 and a stop loss at ₹5,700.…” | Ankush BajajIndependent | Divi's Laboratories Ltd | HIT | ||||
| “Bullish on Divi's Laboratories Ltd, recommending a buy with a target of ₹6,134 and a stop loss at ₹5,867 for a short-ter…” | Jatin GediaSharekhan by BNP Paribas | Divi's Laboratories | MISS | ||||
| “Bullish on Divi's Laboratories, recommending a buy at ₹6142.25 with a target of ₹6555 and a stop loss at ₹5925. The stoc…” | Sumeet BagadiaChoice Equity Broking | Divi's Laboratories | MISS | ||||
| “Bullish on Divi's Laboratories, initiating a 'buy' rating with a target price of ₹6,400, based on a 40x EV/EBITDA multip…” | Citi Research AnalysisCiti Research | Divi's Laboratories | PENDING | ||||
| “Bullish on Divi’s Laboratories, recommending a buy with a target of Rs 5,750 and a stop loss at Rs 5,200.” | Ajit MishraReligare Broking | Divi's Laboratories Ltd | PENDING | ||||
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Divi's Laboratories, setting a target price of ₹7,150, implying an almost 19% upside. The recommendation is b…” | Jefferies AnalysisJefferies | Divi's Laboratories | HIT |
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Divi's Laboratories for the medium term, with a target price of ₹8,300. The company is positioned as a CDMO l…” | Rahul GhoseHedged.in | Divi's Laboratories | — | |
| “Bullish on Indian pharmaceutical stocks, specifically Divi's Laboratories, for 2026 and for investors with a one-year-pl…” | Sudip BandyopadhyayIndependent | Divi's Laboratories | — | |
| “Citi is positive on Divi's Laboratories, projecting a significant 43% upside potential. This bullish outlook is likely d…” | Citi AnalysisCitigroup Inc. | Divi's Laboratories | — | |
| “Divi's Laboratories has broken out from a downward-sloping trendline, suggesting potential for upward movement. Medium-t…” | ETMarkets AnalysisETMarkets.com | Divi's Laboratories | — | |
| “Citi views the recent correction in Divi's Laboratories as a buying opportunity, projecting a 28% upside for the stock. …” | Citi AnalysisCitigroup Inc. | Divi's Laboratories | — | |
| “Cautious on Divi's Lab due to overstretched valuations, trading 40-50% higher than historical averages, despite potentia…” | Aditya KhemkaInCred Asset Management | Divi's Laboratories Ltd | — | |
| “Maintained a 'Neutral' rating on Divi's Laboratories shares with a price target of ₹6,540. While modeling a 25% earnings…” | Motilal Oswal AnalysisMotilal Oswal Financial Services | Divi's Laboratories | — | |
| “Maintains a 'Hold' rating on Divi's Laboratories with a price target of ₹6,200. The company's Q4 numbers were in line wi…” | Jefferies AnalysisJefferies | Divi's Laboratories | — | |
| “Maintains a 'buy' rating on Divi's Laboratories, projecting an upside of up to 19%. This positive outlook suggests a bul…” | Citi AnalysisCitigroup Inc. | Divi's Laboratories | — | |
| “Bullish on Divi’s Laboratories Ltd, recommending a buy in the ₹5,800–5,950 range with a profit goal of ₹6,850 and a stop…” | Marketsmith India AnalysisMarketsmith India | Divi's Laboratories Ltd | — | |
| “Recommends buying Divi’s Laboratories Ltd within the ₹5,800–5,950 range, targeting a profit goal of ₹6,850 with a stop l…” | Marketsmith India AnalysisMarketsmith India | Divi's Laboratories Ltd | — | |
| “Initiates an 'outperform' rating on Divi's Labs, Suven Pharma, Blue Jet Healthcare, and Syngene, expecting them to outpe…” | Macquarie AnalysisMacquarie Capital Securities | Divi's Laboratories | — | |
| “Macquarie has initiated coverage on Indian CRDMO companies with an 'Outperform' rating, assigning price targets that imp…” | Macquarie AnalysisMacquarie Capital Securities | Divi's Laboratories | — | |
| “Maintained a 'Neutral' rating on Divi's Labs with a target price of ₹5,925. The brokerage raised FY25-28 EPS estimates b…” | Goldman Sachs AnalysisGoldman Sachs Group Inc. | Divi's Laboratories | — | |
| “Bullish on Divi's Labs, expecting another 15% run-up from current levels, as its numbers were good and in line with expe…” | Rahul ShahMotilal Oswal Financial Services | Divi's Laboratories | — | |
| “Divi's Laboratories remains Citi's top pharma pick, with an expectation of 15% more upside. The company's strong positio…” | Citi AnalysisCitigroup Inc. | Divi's Laboratories | — | |
| “Bullish on Divi's Laboratories, noting an immediate near-term hurdle around ₹6,150. If the stock surpasses this level, t…” | Ruchit Jain5paisa | Divi's Laboratories | — |
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Kiran Satchandra Divi B. Pharm., M.Pharm
Headquarters
Hyderabad
Employees
11,565
Website
divislabs.comExchange
View on NSE ↗Key stats
Market cap
₹2.66 L Cr
P/E ratio (TTM)
90.8
Dividend yield
0.30%
EPS (TTM)
₹110.21
Beta (1Y · daily vs NIFTY 50)
0.63
Beta (5Y · monthly vs NIFTY 50)
0.78
Shares float
10.93 Cr
EPS · quarter ended Jun 2026
₹33.95
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹6,969.40 Cr | ₹8,959.83 Cr | ₹7,767.51 Cr | ₹7,845.00 Cr | ₹9,360.00 Cr | ₹10,560.00 Cr | |
EBITDA | ₹2,922.50 Cr | ₹3,995.81 Cr | ₹2,712.48 Cr | ₹2,544.00 Cr | ₹3,320.00 Cr | ₹3,874.00 Cr |
| ₹1,984.29 Cr | ₹2,960.45 Cr | ₹1,823.38 Cr | ₹1,600.00 Cr | ₹2,191.00 Cr | ₹2,568.00 Cr | |
Diluted EPS | ₹74.75 | ₹111.52 | ₹68.69 | ₹60.27 | ₹82.53 | ₹96.75 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,774.07 Cr | ₹13,374.71 Cr | ₹14,438.77 Cr | ₹15,460.00 Cr | ₹16,921.00 Cr | ₹20,019.00 Cr | |
| ₹4.48 Cr | ₹3.69 Cr | ₹3.26 Cr | ₹3.00 Cr | ₹4.00 Cr | ₹7.00 Cr | |
Stockholders' equity | ₹9,294.61 Cr | ₹11,728.18 Cr | ₹12,767.09 Cr | ₹13,571.00 Cr | ₹14,969.00 Cr | ₹16,761.00 Cr |
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹1,946.93 Cr | ₹1,911.80 Cr | ₹2,460.00 Cr | ₹1,261.00 Cr | ₹1,653.00 Cr | ₹2,738.00 Cr | |
Investing cash flow | ₹75.13 Cr | ₹-2,194.92 Cr | ₹-2,707.62 Cr | ₹-269.00 Cr | ₹-804.00 Cr | ₹-2,219.00 Cr |
| ₹-34.89 Cr | ₹-532.44 Cr | ₹-797.00 Cr | ₹-799.00 Cr | ₹-799.00 Cr | ₹-804.00 Cr | |
Capital expenditure | ₹-956.03 Cr | ₹-713.20 Cr | ₹-473.02 Cr | ₹-1,003.00 Cr | ₹-1,438.00 Cr | ₹-2,520.00 Cr |
End cash position | ₹2,030.32 Cr | ₹1,214.76 Cr | ₹169.70 Cr | ₹363.00 Cr | ₹413.00 Cr | ₹128.00 Cr |
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 21(2Q) | Mar 22–Mar 23(5Q) | Jun 23–Sep 23(2Q) | Dec 23–Mar 24(2Q) | Jun 24 | Sep 24–Sep 25(5Q) | Dec 25–Jun 26(3Q) |
|---|---|---|---|---|---|---|---|
| Promoter | 51.95% | 51.94% | 51.93% | 51.92% | 51.90% | 51.89% | 51.88% |
| Public | 48.05% | 48.06% | 48.07% | 48.08% | 48.10% | 48.11% | 48.12% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.